Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by sreepspjon Mar 17, 2017 12:04pm
484 Views
Post# 25993841

Future

FutureHello all.
I have been an RVX stockholder for 10+ years, regularly reading through Stockhouse, Investor Village, and Agoracom comments. My background is risk assessment, including financial and medical.  I have gone through the highs and lows along with many of you (never understood how Clevland Clinic got away with their poor performance).
Having read the comments on RVX and Zenith potential, I am surprised by the extremley conservative comments on the valuation of these companies.  I would be disappointed if these companies "potential" is in the $3b range.  RVX and Zenith are on the verge of setting new insights into medical technology. The medications will touch on an incredible array:  cardiovascular, cerebrovascular, neurological, gastro-intestincal, genitourinary.  Sales for the top medications can reach $20b U.S., and with patents reaching 15 years, valuations will sky rocket.  Net profit is much greater than 50% of yearly new sales, and the potential for 5+ new drug medications over the next 5 years is staggering.  My valuation comes into the $100's of billions.
I am not a stock pusher, and have not commented on any other stocks I own.  My apologies for what these comments may bring, but others should be aware of the potential of RVX and Zenith.
My opinion only.
Bullboard Posts